Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 Nov;66(6):552–571. doi: 10.1016/j.curtheres.2005.12.012

Effects of pentosan polysulfate in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled pilot study

Peter Ghosh 1,*, Jack Edelman 2, Lyn March 1, Margaret Smith 1
PMCID: PMC3965979  PMID: 24678076

Abstract

Background:

Recent recommendations from the Group for the Respect of Excellence and Ethics in Science for the clinical assessment of the effects of disease-modifying osteoarthritis (OA) drugs suggest that improvement in joint space narrowing, pain, and function relative to a control group should be the primary end points.

Objective:

The aim of this study was to assess the ability of sodium pentosan polysulfate (NaPPS) to improve pain and function in patients with OA of the knee.

Methods:

This randomized, double-blind, placebo-controlled pilot study was performed at the Queen Elizabeth II Medical Centre, Perth, Australia. Patients aged ≥18 years with OA of the knee were randomly assigned to receive NaPPS 3 mg/kg or Ringer's solution (control), IM QW for 4 weeks. Efficacy was assessed at enrollment and weekly during the 4 weeks of treatment and at weeks 8, 12, 16, and 24. Seven direct clinical assessments were made, including intensity of early morning joint stiffness, pain at rest, and pain on walking. A 10-cm visual analog scale (VAS) was used to assess pain at rest and on walking and early morning joint stiffness. Response was defined as a change from baseline in VAS score ≥2 cm. Function was assessed using the 10-cm VAS to rate 13 activities of daily living (ADLs), including stair climbing and domestic chores. Patient global assessment of the overall effectiveness of the study drug comprised a 4-point Likert scale (0 = not effective to 3 = maximally effective). An aggregate score for all ADL functions was calculated as the mean change from baseline score of all of the ADLs as determined at 4, 8, 12, 16, and 24 weeks after commencement of the study. For tolerability monitoring, hematology and biochemistry were used, and patients were questioned about adverse events at each visit.

Results:

A total of 114 patients were enrolled (83 women, 31 men; mean [SD] age, 63.3 [1.5] years; NaPPS group, 54 patients; control group, 60 patients). Significant differences in scores of 3 of the 7 direct clinical assessments were found between the 2 groups (duration of joint stiffness at 4, 8, 12, and 16 weeks [all, P:5 0.015]; pain at rest at 8, 12, 16, and 24 weeks [all, P ≤ 0.017]; and patient global assessment at 4, 8, 12, 16, and 24 weeks [all, P <- 0.006]). The rates of trial continuation were higher in the NaPPS group compared with those in the control group at 8, 12, and 24 weeks (all, P < 0.05). Mean scores for 3 of 13 ADLs were significantly higher in the NaPPS group compared with those in the control group at weeks 8 and 12 (all, P ≤ 0.03). On combining all of the ADL scores, functional improvement from baseline was found at weeks 8 and 12 in the NaPPS group (both, P = 0.02). Mild bruising at the injection site occurred in <1% of patients in both treatment groups.

Conclusions:

In this pilot study, 4 weekly injections of NaPPS were associated with significantly improved duration of joint stiffness and pain at rest compared with controls for 20 weeks after the cessation of treatment, and significantly improved pain on walking and overall function for 8 weeks after the cessation of treatment in these patients with OA of the knee.

Key words: osteoarthritis, pentosan polysulfate, symptomatic relief

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

References

  • 1.Lawrence R.C., Hochberg M.C., Kelsey J.L. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol. 1989;16:427–441. [PubMed] [Google Scholar]
  • 2.Bagge E., Bjelle A., Eden S., Svanborg A. Osteoarthritis in the elderly: Clinical and radiological findings in 79 and 85 year olds. Ann Rheum Dis. 1991;50:535–539. doi: 10.1136/ard.50.8.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Felson D.T. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am. 2004;42:1–9. doi: 10.1016/S0033-8389(03)00161-1. [DOI] [PubMed] [Google Scholar]
  • 4.March L.M., Bachmeier C.J. Economics of osteoarthritis: A global perspective. Baillieres Clin Rheumatol. 1997;11:817–834. doi: 10.1016/s0950-3579(97)80011-8. [DOI] [PubMed] [Google Scholar]
  • 5.Yelin E. The economics of osteoarthritis. In: Brandt K.D., Doherty M., Lohmander L.S., editors. Osteoarthritis. 2nd ed. Oxford Press; New York, NY: 2003. pp. 23–30. [Google Scholar]
  • 6.Brooks P.M. Impact of osteoarthritis on individuals and society: How much disability? Social consequences and health economic implications. Curr Opin Rheumatol. 2002;14:573–577. doi: 10.1097/00002281-200209000-00017. [DOI] [PubMed] [Google Scholar]
  • 7.Yuan G.H., Masuko-Hongo K., Kato T., Nishioka K. Immunologic intervention in the pathogenesis of osteoarthritis. Arthritis Rheum. 2003;48:602–611. doi: 10.1002/art.10768. [DOI] [PubMed] [Google Scholar]
  • 8.Brandt K.D. Should nonsteroidal anti-inflammatory drugs be used to treat osteoarthritis. Rheum Dis Clin North Am. 1993;19:29–44. [PubMed] [Google Scholar]
  • 9.Huskisson E.C., Berry H., Gishen P., Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis (LINK) Study Group Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. J Rheumatol. 1995;22:1941–1946. [PubMed] [Google Scholar]
  • 10.Lichtenstein D.R., Syngal S., Wolfe M.M. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum. 1995;38:5–18. doi: 10.1002/art.1780380103. [DOI] [PubMed] [Google Scholar]
  • 11.Davies N.M., Wallace J.L. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity. New insights into an old problem. J Gastroenterol. 1997;32:127–133. doi: 10.1007/BF01213310. [DOI] [PubMed] [Google Scholar]
  • 12.Graham D.J., Campen D., Hui R. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet. 2005;365:475–481. doi: 10.1016/S0140-6736(05)17864-7. [DOI] [PubMed] [Google Scholar]
  • 13.Kimmel S.E., Berlin J.A., Reilly M. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005;142:157–164. doi: 10.7326/0003-4819-142-3-200502010-00005. [DOI] [PubMed] [Google Scholar]
  • 14.Solomon S.D., McMurray J.J., Pfeffer M.A., Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080. doi: 10.1056/NEJMoa050405. [DOI] [PubMed] [Google Scholar]
  • 15.Altman R., Brandt K., Hochberg M. Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996;4:217–243. doi: 10.1016/s1063-4584(05)80101-3. [DOI] [PubMed] [Google Scholar]
  • 16.Altman R. Measurement of structural (disease) modification in osteoarthritis. Osteoarthritis Cartilage. 2004;12(Suppl A):S69–S76. doi: 10.1016/j.joca.2003.09.011. [DOI] [PubMed] [Google Scholar]
  • 17.Abadie E., Ethgen D., Avouac B., Group for the Respect of Excellence and Ethics in Science. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12:263–268. doi: 10.1016/j.joca.2004.01.006. [DOI] [PubMed] [Google Scholar]
  • 18.Altman R.D., Abadie E., Avouac B. Total joint replacement of the hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage. 2005;13:13–19. doi: 10.1016/j.joca.2004.10.012. [DOI] [PubMed] [Google Scholar]
  • 19.Burkhardt D., Ghosh P. Laboratory evaluation of antiarthritic agents as potential chondroprotective agents. Semin Arthritis Rheum. 1987;17(Suppl 1):3–34. [PubMed] [Google Scholar]
  • 20.Ghosh P., Smith M., Wells C. Second line agents in osteoarthritis. In: Dixon J.S., Furst D.E., editors. Second-Line Agents in the Treatment of Rheumatic Diseases. Dekker; New York, NY: 1992. pp. 363–427. [Google Scholar]
  • 21.Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum. 1999;28:211–267. doi: 10.1016/s0049-0172(99)80021-3. [DOI] [PubMed] [Google Scholar]
  • 22.Reginster J.Y., Deroisy R., Rovati L.C. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet. 2001;27:251–256. doi: 10.1016/S0140-6736(00)03610-2. [DOI] [PubMed] [Google Scholar]
  • 23.Dougados M., Nguyen M., Berdah L., Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip (ECHODIAH) Investigators Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three year, placebo controlled trial. Arthritis Rheum. 2001;44:2539–2547. doi: 10.1002/1529-0131(200111)44:11<2539::aid-art434>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  • 24.Mazzuca S.A., Brandt K.D., Buckwalter K.A., Lequesne M. Pitfalls in the accurate measurement of joint space narrowing in semiflexed, anteroposterior radiographic imaging of the knee. Arthritis Rheum. 2004;50:2508–2515. doi: 10.1002/art.20363. [DOI] [PubMed] [Google Scholar]
  • 25.Kellgren J.H., Lawrence J.S. Radiological assessment of osteoarthrosis. Ann Rheum Dis. 1957;16:494–502. doi: 10.1136/ard.16.4.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Theiler R., Ghosh P., Brooks P. Clinical, biochemical and imaging methods of assessing osteoarthritis and clinical trials with agents claiming ‘chondromodulating’ activity. Osteoarthritis Cartilage. 1994;2:1–23. doi: 10.1016/s1063-4584(05)80002-0. [DOI] [PubMed] [Google Scholar]
  • 27.Kalbhen D.A. The biochemical and pharmacological basis of the anti-phlogistic/ antirheumatic effect of pentosan polysulphate [in German] Wien Klin Wochenschr. 1978;90:101–105. [PubMed] [Google Scholar]
  • 28.Berthoux F.C., Freyria A.M., Traeger J. Anticomplement activity of a polyanion: Pentosan sulfate polyester. III. Mechanism of functional inactivation of the different properdin and complement system fractions. Pathol Biol (Paris) 1977;25:179–184. [PubMed] [Google Scholar]
  • 29.Kilgore K.S., Naylor K.B., Tanhehco E.J. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in rabbit perfused heart. J Pharmacol Exp Ther. 1998;285:987–994. [PubMed] [Google Scholar]
  • 30.Freyburger G., Larrue F., Manciet G. Hemorheological changes in elderly subjectseffects of pentosan polysulfate and possible role of leucocyte arachidonic acid metabolism. Thromb Haemost. 1987;57:322–325. [PubMed] [Google Scholar]
  • 31.Henderson W.R., Jr. The role of leukotrienes in inflammation. Ann Intern Med. 1994;121:684–697. doi: 10.7326/0003-4819-121-9-199411010-00010. [DOI] [PubMed] [Google Scholar]
  • 32.Skelly M.M., Hawkey C.J. COX-LOX inhibition: Current evidence for an emerging new therapy. Int J Clin Pract. 2003;57:301–304. [PubMed] [Google Scholar]
  • 33.Halse T. Activation of fibrinolysis and thrombolysis by polysaccharide sulfuric acid esters (heparin, heparinoid) Arzneimittelforschung. 1962;12:574–582. [in German] [PubMed] [Google Scholar]
  • 34.Bullough P.G., DiCarlo E.F. Subchondral avascular necrosis: A common cause of arthritis. Ann Rheum Dis. 1990;49:412–420. doi: 10.1136/ard.49.6.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Cheras P.A., Freemont A.J., Sikorski J.M. Intraosseous thrombosis in ischemic necrosis of bone and osteoarthritis. Osteoarthritis Cartilage. 1993;1:219–232. doi: 10.1016/s1063-4584(05)80328-0. [DOI] [PubMed] [Google Scholar]
  • 36.Ghosh P., Cheras P.A. Vascular mechanisms in osteoarthritis. Best Pract Res Clin Rheumatol. 2001;15:693–709. doi: 10.1053/berh.2001.0188. [DOI] [PubMed] [Google Scholar]
  • 37.Kiaer T. The intraosseous circulation and pathogenesis of osteoarthritis. Med Sci Res. 1987;15:759–763. [Google Scholar]
  • 38.Arnoldi C.C. Vascular aspects of degenerative joint disorders. A synthesis. Acta Orthop Scand Suppl. 1994;261:1–82. [PubMed] [Google Scholar]
  • 39.Arnoldi C.C., Lemperg K., Linderholm H. Intraosseous hypertension and pain in the knee. J Bone Joint Surg Br. 1975;57:360–363. [PubMed] [Google Scholar]
  • 40.Anderson J.M., Edelman J., Ghosh P. Effects of pentosan polysulfate on peripheral blood leukocyte populations and mononuclear cell procoagulant activity in patients with osteoarthritis. Curr Ther Res Clin Exp. 1997;58:93–107. [Google Scholar]
  • 41.Edelman J., Anderson J., Ghosh P. Disease modification in osteoarthritis: Relationship of macrophage procoagulant activity and haematological parameters to symptoms in patients receiving pentosan polysulfate. Osteoarthritis Cartilage. 1996;4:iv–v. (Suppl) [Google Scholar]
  • 42.Verbruggen G., Veys E.M. Intra-articular injection of pentosanpolysulphate results in increased hyaluronan molecular weight in joint fluid. Clin Exp Rheumatol. 1992;10:249–254. [PubMed] [Google Scholar]
  • 43.Adam N., Ghosh P., Swain M. The effects of intra-articular pentosan polysulphate (Cartrophen) on synovial fluid visco-elasticity and hyaluronan molecular weight in patients with gonarthritis. Osteoarthritis Cartilage. 1996;4:viii. (Suppl) [Google Scholar]
  • 44.Ghosh P., Guidolin D. Potential mechanism of action of intra-articular hyaluronan in osteoarthritis: Are the effects molecular weight dependent? Semin Arthritis Rheum. 2002;32:10–37. doi: 10.1053/sarh.2002.33720. [DOI] [PubMed] [Google Scholar]
  • 45.Balazs E.A., Watson D., Duff I.F., Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum. 1967;10:357–376. doi: 10.1002/art.1780100407. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES